REFERENCES
1. Norris AM, Laing EJ, Valli VE, et al. Canine bladder and urethral tumors: a retrospective study of 115 cases (1980-1985).
J Vet Intern Med 1992;6:145-153.
2. Valli VE, Norris A, Jacobs RM, et al. Pathology of canine bladder and urethral cancer and correlation with tumour progression
and survival. J Comp Pathol 1995;113:113-130.
3. Knapp DW, Glickman NW, DeNicola DB, et al. Naturally occurring canine transitional cell carcinoma of the urinary bladder.
A relevant model of human invasive bladder cancer—a prospective study. Urol Oncol Semin Orig Invest 2000;5:47-59.
4. Glickman LT, Raghavan M, Knapp DW, et al. Herbicide exposure and the risk of transitional cell carcinoma of the urinary bladder
in Scottish Terriers. J Am Vet Med Assoc 2004;224:1290-1297.
5. Raghavan M, Knapp DW, Dawson MH, et al. Topical flea and tick pesticides and the risk of transitional cell carcinoma of the
urinary bladder in Scottish Terriers. J Am Vet Med Assoc 2004;225:389-394.
6. Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997;13:291-298.
7. Macy DW, Withrow SJ, Hoopes J. Transitional cell carcinoma of the bladder associated with cyclophosphamide administration.
J Am Anim Hosp Assoc 1983;19:965-969.
8. Glickman LT, Shofer FS, McKee LJ, et al. Epidemiologic study of insecticide exposures, obesity, and risk of bladder cancer
in household dogs. J Toxicol Environ Health 1989;28:407-414.
9. Hartge P, Silverman D, Hoover R, et al. Changing cigarette habits and bladder cancer risk: a case-control study. J Natl Cancer Inst 1987;78:1119-1125.
10. Inoue K, Kamada M, Slaton JW, et al. The prognostic value of angiogenesis and metastasis-related genes for progression of
transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 2002;8:1863-1870.
11. Lutsenko SV, Kiselev SM, Severin SE. Molecular mechanisms of tumor angiogenesis. Biochemistry (Mosc) 2003;68:286-300.
12. Mohammed SI, Craig BA, Mutsaers AJ, et al. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy
on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol Cancer Ther 2003;2:183-188.
13. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000;30:3-21.
14. Khan KN, Knapp DW, DeNicola DB, et al. Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder
in dogs. Am J Vet Res 2000;61:478-481.
15. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005;5:713-725.
16. Greene SN, Purdue University, West Lafayette, Ind: Personal communication, April 2006.
17. Nyland TG, Wallack ST, Wisner ER. Needle-tract implantation following us-guided fine-needle aspiration biopsy of transitional
cell carcinoma of the bladder, urethra, and prostate. Vet Radiol Ultrasound 2002;43:50-53.
18. Henry CJ, Tyler JW, McEntee MC, et al. Evaluation of a bladder tumor antigen test as a screening test for transitional cell
carcinoma of the lower urinary tract in dogs. Am J Vet Res 2003;64:1017-1020.
19. Billet JP, Moore AH, Holt PE. Evaluation of a bladder tumor antigen test for the diagnosis of lower urinary tract malignancies
in dogs. Am J Vet Res 2002;63:370-373.
20. Borjesson DL, Christopher MM, Ling GV. Detection of canine transitional cell carcinoma using a bladder tumor antigen urine
dipstick test. Vet Clin Pathol 1999;28:33-38.
21. Lamb CR, Trower ND, Gregory SP. Ultrasound-guided catheter biopsy of the lower urinary tract: technique and results in 12
dogs. J Small Anim Pract 1996;37:413-416.
22. Mitten RW, Riedesel DH, Flatt RE. Cavitating pulmonary metastases in a dog. J Am Vet Med Assoc 1978;173:203-205.
23. Walter PA, Haynes JS, Feeney DA, et al. Radiographic appearance of pulmonary metastases from transitional cell carcinoma
of the bladder and urethra of the dog. J Am Vet Med Assoc 1984;185:411-418.
24. Goto K, Konomoto T, Hayashi K, et al. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development
of multiple carcinomas. Mod Pathol 1997;10:428-437.
25. Knapp DW, Purdue University, West Lafayette, Ind: Personal communication, April 2006.
26. Cornell KK. Cystotomy, partial cystectomy, and tube cystostomy. Clin Tech Small Anim Pract 2000;15:11-16.
27. Stone EA, Withrow SJ, Page RL, et al. Ureterocolonic anastomosis in ten dogs with transitional cell carcinoma. Vet Surg 1988;17:147-153.
28. Ko GY, Kim GC, Seo TS, et al. Covered, retrievable, expandable urethral nitinol stent: feasibility study in dogs. Radiology 2002;223:83-90.
29. Liptak JM, Brutscher SP, Monnet E, et al. Transurethral resection in the management of urethral and prostatic neoplasia in
6 dogs. Vet Surg 2004;33:505-516.
30. Goya N, Ishikawa N, Tomizawa Y, et al. Electrovaporization using a rollerball electrode for flat or small papillary tumors
of the bladder: basic study in dogs. J Endourol 2001;15:951-955.
31. Knapp DW, Richardson RC, Chan TC, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder.
J Vet Intern Med 1994;8:273-278.
32. Mutsaers AJ, Mohammed SI, DeNicola DB, et al. Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression
are not associated with the response of canine naturally occurring invasive urinary bladder cancer to cyclooxygenase inhibitor
therapy. Prostaglandins Leukot Essent Fatty Acids 2005;72:181-186.
33. Chun R, Knapp DW, Widmer WR, et al. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18
cases (1983-1993). J Am Vet Med Assoc 1996;209:1588-1591.
34. Moore AS, Cardona A, Shapiro W, et al. Cisplatin (cisdiamminedichloroplatinum) for treatment of transitional cell carcinoma
of the urinary bladder or urethra. A retrospective study of 15 dogs. J Vet Intern Med 1990;4:148-152.
35. Shapiro W, Kitchell BE, Fossum TW, et al. Cisplatin for treatment of transitional cell and squamous cell carcinomas in dogs.
J Am Vet Med Assoc 1988;193:1530-1533.
36. Chun R, Knapp DW, Widmer WR, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary
bladder. J Vet Intern Med 1997;11:279-283.
37. Hammer AS, Couto CG, Ayl RD, et al. Treatment of tumor-bearing dogs with actinomycin D. J Vet Intern Med 1994;8:236-239.
38. Rocha TA, Mauldin GN, Patnaik AK, et al. Prognostic factors in dogs with urinary bladder carcinoma. J Vet Intern Med 2000;14:486-490.
39. Henry CJ, McCaw DL, Turnquist SE, et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive
urinary bladder carcinoma. Clin Cancer Res 2003;9:906-911.
40. Ogilvie GK, Obradovich JE, Elmslie RE, et al. Efficacy of mitoxantrone against various neoplasms in dogs. J Am Vet Med Assoc 1991;198:1618-1621.
41. Helfand SC, Hamilton TA, Hungerford LL, et al. Comparison of three treatments for transitional cell carcinoma of the bladder
in the dog. J Am Anim Hosp Assoc 1994;30:270-275.
|
Featuring Information from:
